Crispr stocks

The best CRISPR stocks depend on your portfolio and investment goals — while volatility can be ideal for day traders, long-term investors will want to look to stocks with steadier gains over time.

Our picks for the best CRISPR stocks

We round up a selection of stocks in or related to the gene editing industry, weighting the list more heavily towards popular mid- and large-cap US stocks.

---

1. Crispr Therapeutics (CRSP)

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.

• Previous close price: $64.66
• Market capitalization: $5,003,301,376
• 1 year performance: 18.53%

Buy CRSP stock on National Bank Direct Brokerage

---

2. Editas Medicine (EDIT)

Editas Medicine, Inc. , a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology.

• Previous close price: $56.52
• Market capitalization: $627,859,968
• 1 year performance: N/A

Buy EDIT stock on National Bank Direct Brokerage

---

3. Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

• Previous close price: $725.05
• Market capitalization: $82,124,513,280
• 1 year performance: 9.99%
• P/E ratio: 20.5366

Buy REGN stock on National Bank Direct Brokerage

---

4. Cellectis (CLLS)

Cellectis S. A. , a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells.

• Previous close price: $14.44
• Market capitalization: $104,808,496
• 1 year performance: -44.04%

Buy CLLS stock on National Bank Direct Brokerage

---

5. Beam Therapeutics Inc (BEAM)

Beam Therapeutics Inc. , a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency.

• Previous close price: $98.05
• Market capitalization: $2,467,160,576
• 1 year performance: N/A

Buy BEAM stock on National Bank Direct Brokerage

---

6. Bluebird bio (BLUE)

bluebird bio, Inc. , a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.

• Previous close price: $30.43
• Market capitalization: $378,826,720
• 1 year performance: N/A

Buy BLUE stock on National Bank Direct Brokerage

---

7. Sangamo Therapeutics (SGMO)

Sangamo Therapeutics, Inc. , a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.

• Previous close price: $12.01
• Market capitalization: $216,500,752
• 1 year performance: -65.95%

Buy SGMO stock on National Bank Direct Brokerage

Buy CRISPR stocks from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

Bottom line

While it's possible to turn a profit investing in CRISPR stocks, keep in mind that — like any investment — CRISPR stocks are not immune to risk. These stocks are subject to fluctuating conditions — both in the market and in the gene editing industry, so carefully vet your picks before you invest. And if you're new to investing, or if it's been awhile since you've taken a critical look at your investing accounts, compare brokers to make sure you're getting the best features in your trading account.